Long-acting GHRH analogue with an albumin-binding DAC group
PRODUCT PROFILE
CJC-1295 DAC
Price range: £32.99 through £39.99
CJC-1295 DAC is long-acting ghrh analogue with an albumin-binding dac group. Researchers examine it in relation to sustained elevation of endogenous gh and igf-1 while retaining pituitary pulsatility.
Why it is distinct
Its albumin-binding extension creates sustained exposure, unlike CJC-1295 No DAC or sermorelin.
- Evidence stageEarly human evidence
- AvailabilityAvailable · 10 in stock
- Batch recordPublished after verification
- DispatchConfirmed at checkout
PRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
CJC-1295 DAC is long-acting ghrh analogue with an albumin-binding dac group. Researchers examine it in relation to sustained elevation of endogenous gh and igf-1 while retaining pituitary pulsatility.
Research focus+
Researchers study its effects on growth hormone and IGF-1. The DAC attachment makes it last much longer than CJC-1295 No DAC.
How the mechanism differs+
Activates GHRH receptors and covalently associates with circulating albumin, extending exposure for days.
Evidence and limitations+
Randomised early human pharmacology demonstrated prolonged GH and IGF-1 increases; clinical outcome evidence remains limited.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers study its effects on growth hormone and IGF-1. The DAC attachment makes it last much longer than CJC-1295 No DAC.
Activates GHRH receptors and covalently associates with circulating albumin, extending exposure for days.
Its albumin-binding extension creates sustained exposure, unlike CJC-1295 No DAC or sermorelin.
Randomised early human pharmacology demonstrated prolonged GH and IGF-1 increases; clinical outcome evidence remains limited.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Experimental
Follistatin 344
£76.001 mgBatch file pendingA ligand-binding inhibitor of the activin/myostatin system, not a GH or IGF secretagogue.
UnavailableAsk about availability -
Early human evidence
CJC-1295 No DAC
Price range: £25.99 through £32.995 mgBatch file pendingShort-duration GHRH signalling, in contrast with albumin-bound, long-acting CJC-1295 DAC.
UnavailableAsk about availability This product has multiple variants. The options may be chosen on the product page -
Established
Sermorelin
£49.005 mgBatch file pendingClosest to the natural active GHRH sequence and shorter acting than tesamorelin or CJC-1295 DAC.
UnavailableAsk about availability -
Early human evidence
Hexarelin
£51.005 mgBatch file pendingA potent older GHRP with less hormonal selectivity than ipamorelin.
UnavailableAsk about availability